DMD #10397
5 liver by MEIs. MEIs differentially regulate hepatic expression of individual UGT isoforms, though no one transcriptional pathway dominated. In duodenum, MEIs had minimal effects on UGT expression.
Individuals are continually exposed to potentially toxic endogenous and xenobiotic compounds. Thus, individuals require a means of eliminating such compounds from the body. UDP-glucuronosyltransferases (UGTs) comprise a superfamily of phase-II biotransformation enzymes that generally function to detoxify by catalyzing the glucuronidation of structurally diverse compounds, making them more water-soluble, and more easily excreted. UGTs are mainly expressed in liver and gastrointestinal tract and are involved in the metabolic homeostasis of endogenous compounds including bilirubin, steroid hormones, and thyroid hormone, as well as the metabolism of a wide variety of xenobiotics including opioids, flavonoids, acetaminophen, non-steroidal anti-inflammatory drugs, and carcinogens (Dutton, 1980; Clarke and Burchell, 1987; Mackenzie and Rodbourn, 1990; Burchell et al., 1991; Emi et al., 1995; Grams et al., 2000; Shelby et al., 2003) .
To date, there are numerous reports of increased UGT activity in response to xenobiotic exposure. Many of these xenobiotics are known as microsomal enzyme inducers (MEIs), which are classic inducers of phase-I biotransformation enzymes, most notably cytochrome P450s (CYPs). Induction of CYPS by MEIs is thought to be due mostly to transcriptional activation (Nebert and Gonzalez, 1987) .
UGTs may be coordinately regulated with CYPs and other phase-I enzymes through the same transcriptional pathways.
DMD #10397 8 and nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2). AhR is well known for its ability to induce the phase-I biotransformation enzyme CYP1A1 (Jaiswal et al., 1985; Fernandez-Salguero et al., 1996) . Highly lipophillic compounds such as the herbicide contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and planar polychlorinated biphenyls (PCBs) bind to AhR, and trigger its activation and subsequent binding to xenobiotic response elements (XREs). Contrary to AhR, which can induce both phase-I and -II enzymes, Nrf2 is mainly involved in the regulation of phase-II enzymes. Alterations in the oxidative environment within the cell can cause the activation/release of Nrf2 from sequestration within the cytosol. Nrf2 subsequently translocates to the nucleus and forms a complex with small Maf proteins that binds antioxidant/electrophile response elements and turns on the antioxidant response gene battery (Itoh et al., 1999) .
Transcriptional up-regulation of biotransformation enzymes by MEIs occurs through nuclear receptor-mediated pathways including CAR, PXR, and PPARα, as well as transcription factors such as AhR, and Nrf2. However for some MEIs, such as the CYP2E inducers isoniazid and streptozotocin, no transcriptional pathway has been identified.
Induction of phase-II biotransformation enzymes, such as UGTs, may be coordinately regulated with phase-I biotransformation enzymes through the same transcriptional pathway. Inducibility of individual UGT isoforms by MEIs and potential mechanisms of induction are not completely understood. Induction of UGT activity reportedly occurs in both liver and duodenum, tissues in which DMD #10397
UGTs are predominantly expressed. Therefore, the purpose of this study was to determine the inducibility of individual UGT isoforms in liver and duodenum by
MEIs that act through various transcriptional pathways. Klaassen, 2002) and UGT1A3, 8, 2B2, 3, 6, 8, and 12 were described previously (Shelby et al., 2003) .
Materials and Methods

Chemicals
Total RNA (1 µg/µl; 10 µl/well; n= 4-5) was allowed to hybridize to the probe sets overnight at 53°C. Subsequent hybridization steps were carried out and alkaline phosphatase substrate was added. Statistics. Analysis of variance followed by Duncan's multiple range post hoc analysis was used to determine statistical differences between control groups and between control and treated animals. Statistical significance was accepted at p < 0.05 and is denoted by an asterisk (*).
This article has not been copyedited and formatted. The final version may differ from this version. mRNA expression in liver was not affected by any MEI treatment (Fig. 1a) .
Similar to UGT1A2, UGT1A3 is barely detectable in liver and predominantly expressed in intestine. Conversely, UGT1A3 mRNA was up-regulated by many
MEIs including all CYP2E1 inducers, two of three AhR and PPARα ligands, and the Nrf2 activator oltipraz (Fig 1a) . Despite this up-regulation, resultant UGT1A3 mRNA levels in liver were still very low. UGT1A5 mRNA was up-regulated by various MEIs including the two CAR activators diallyl sulfide and trans-stilbene oxide, PCN, DEHP, and ethoxyquin (Fig. 1a) . This seemingly sporadic upregulation of UGT1A5 by individual compounds within a class hinders elucidation of specific nuclear receptors involved in the regulation of UGT1A5. UGT1A6
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 1b) . Similar to UGT1A6, UGT1A7 mRNA was upregulated by all AhR ligands and Nrf2 activators, and the CAR activator transstilbene oxide (Fig. 1b) . Like other UGT1A isoforms, UGT1A8 mRNA is barely detectable in liver. UGT1A8 does not appear to be inducible by classic nuclear receptor mechanisms (Fig. 1b) .
Induction of UGT1A mRNA in Duodenum. The effects of MEI treatment on UGT1A mRNA expression in duodenum are shown in Figure 2 . Unlike UGT1A1 mRNA expression in liver, UGT1A1 mRNA was not up-regulated by any MEI treatment in duodenum. Although PFDA and streptozotocin, which induced UGT1A1 mRNA expression in liver, tended to decrease UGT1A1 mRNA in duodenum (Fig. 2a) . UGT1A2 mRNA was up-regulated by the two PXR ligands spironolactone and dexamethasone, the Nrf2 activator oltipraz, and the CYP2E1 inducer isoniazid (Fig. 2a) . In liver, numerous MEIs up-regulated UGT1A3 mRNA levels; however in duodenum only oltipraz was able to induce UGT1A3 mRNA (Fig. 2a) . Similar to the situation with UGT1A3, multiple MEIs induced UGT1A5 mRNA in liver but none induced UGT1A5 mRNA in duodenum (Fig. 2a) .
This was also the case for UGT1A6 and 1A7 (Fig. 2b) . UGT1A8 mRNA was not induced by any MEI treatment (Fig. 2b) .
Induction of UGT2B mRNA in Liver. The effects of MEI treatment on UGT2B mRNA expression in liver are shown in Figure 3 . UGT2B1 mRNA levels were up-regulated by all CAR activators and Nrf2 activators, as well as PCN (Fig. 3a) .
UGT2B2 mRNA levels were not significantly increased by any MEI treatment (Fig. 3A) . UGT2B3 mRNA levels were up-regulated by both Nrf2 activators and the CAR activator trans-stilbene oxide (Fig. 3a) . UGT2B6 mRNA levels were not significantly up-regulated by any MEI treatment. Although both Nrf2 activators and two CAR activators (PCB99 and trans-stilbene oxide) tended to increase UGT2B6 mRNA levels (Fig. 3b) . UGT2B8 mRNA levels were up-regulated by the CAR activator trans-stilbene oxide and the Nrf2 activator oltipraz (Fig. 3b ).
UGT2B12 mRNA levels were up-regulated by the AhR ligand PCB126 and by the two CAR activators PCB99 and trans-stilbene oxide (Fig. 3b) .
Induction of UGT2B mRNA in Duodenum. The effects of MEI treatment on UGT2B mRNA expression in duodenum are shown in Figure 4 . UGT2B1 mRNA levels are barely detectable in duodenum and were not increased by any MEI treatment. However, all four CAR activators tended to increase UGT2B1 mRNA levels (Fig. 4a) . Like UGT2B1, UGT2B2 mRNA is barely detectable in duodenum and was not increased by any MEI treatment (Fig. 4a) . UGT2B3
mRNA was up-regulated by the Nrf2 activator oltipraz and tended to be increased by the Nrf2 activator ethoxyquin (Fig. 4a) . UGT2B6 mRNA levels were not induced by any MEI treatment, but tended to be increased by the Nrf2 activator oltipraz (Fig. 4b) . UGT2B8 mRNA was not up-regulated by any MEI.
However, both Nrf2 activators, the CAR activator diallyl sulfide, and the PXR This article has not been copyedited and formatted. The final version may differ from this version. ligand PCN tended to increase UGT2B8 mRNA levels in duodenum (Fig. 4b ).
UGT2B12 mRNA levels were up-regulated by both Nrf2 activators (Fig. 4b) .
Discussion
The ability of drugs and other chemicals to increase the expression of detoxifying biotransformation enzymes, such as UGTs, and subsequently alter the disposition of both endogenous and xenobiotic compounds, has been of interest for several decades. For instance, in the sixties, administration of the antiepileptic drug phenobarbital to a hyperbilirubinemic infant was shown to increase bilirubin UGT activity resulting in amelioration of hyperbilirubinemia (Yaffe et al., 1966) . With the exception of UGT1A1, most UGT1A isoforms are expressed at low levels in naïve rat liver. Only UGT1A1, 1A5, and 1A6 have appreciable expression in rat liver (Grams et al., 2000; Shelby et al., 2003) . Despite low levels of expression, many of the UGT1A isoforms are inducible in liver. For example, some studies have not detected UGT1A7 in naïve rat liver, but have readily detected it after treatment with oltipraz (Emi et al., 1995; Grove et al., 1997) . Unlike in liver, most UGT1A isoforms have appreciable, if not predominant, expression in intestine (Grams et al., 2000; Shelby et al., 2003) . In contrast, most rat UGT2B isoforms have predominant expression in liver and minimal expression in other tissues (Shelby et al., 2003) . Only UGT2B8 has higher expression in intestine than in liver (Shelby et al., 2003) .
Although CAR and PXR are reportedly expressed in liver and intestine, induction of UGTs by CAR activators and PXR ligands was observed primarily in liver. In duodenum, CAR activators did not induce any UGTs, and only UGT1A2 was induced by PXR ligands. UGT1A2, which is predominantly expressed in intestine and barely detectable in liver (Shelby et al., 2003) , was the only UGT to be induced in duodenum but not liver.
Overall, CAR activators had more effects on UGT mRNA expression in liver than did PXR ligands. UGTs induced in liver by CAR activators include UGT1A1, 1A5, 1A6, 2B1, and 2B12. UGT2B1, which is predominantly expressed in liver, was the only UGT to be induced by all four CAR activators, strongly indicating it This article has not been copyedited and formatted. The final version may differ from this version. is a potential CAR target gene. This is not surprising as UGT2B1 was originally identified by its ability to be induced by phenobarbital, a CAR activator (Mackenzie, 1986) . UGT1A1, 1A5, 1A6, and 2B12, were all induced in liver by at least two of four CAR activators. Interestingly, none of these UGTs were induced by the prototypical CAR activator phenobarbital. However, in the case of UGT1A1, other groups have also reported a lack of induction of rat UGT1A1 mRNA following phenobarbital treatment (Emi et al., 1995) . Furthermore, other investigators have reported that rat bilirubin glucuronidation activity is not readily inducible by phenobarbital, which is in contrast to bilirubin glucuronidation activity in humans (Bock et al., 1973) . UGT2B12 has been reported previously to be inducible in liver by phenobarbital though induction was not observed in the present study (Green et al., 1995) .
UGT1A1, 1A5, and 2B1, were induced in liver by the PXR ligand PCN, and only UGT1A1 was also induced by spironolactone. In another study, northern and western blot analysis revealed induction of UGT1A1, 1A5, and 2B1 following spironolactone treatment (Catania et al., 2003) . Thus, rat UGT1A1, 1A5, and 2B1 may be both CAR and PXR target genes in liver, however further evidence is needed. Hepatic expression of UGT1A6 and 2B12 is also potentially regulated by CAR, although PXR does not appear to regulate these genes.
Unlike CAR and PXR, PPARα does not seem to play a major role in the body's defense mechanism against xenobiotics. PPARα is activated by fatty acids and compounds referred to as peroxisome proliferators (PP) for their ability to produce a pleiotropic response including hepatomegaly, peroxisome proliferation, and induction of specific enzymes involved in both peroxisomal β-oxidation and microsomal ω-oxidation (Cyp4A) of fatty acids (Reddy et al., 1982; Van Rafelghem et al., 1987; Chinje et al., 1994; Johnson et al., 1996) . The pleiotropic response, normally observed after administration of PPs such as clofibrate, is not observed in PPARα-null mice (Lee et al., 1995) . Moreover, liver and kidney, which express high amounts of PPARα, are the tissues that are most responsive to PPs (Kliewer et al., 1994) . As PPARα is not expressed appreciably in intestine, induction of UGTs in intestine by PPARα agonists was not observed or expected.
Despite its seemingly predominant role in regulating genes involved in fatty acid metabolism and transport, PPARα can also mediate induction of biotransformation enzymes. Recently UGT1A9, a human UGT that metabolizes fibrates, was shown to be induced by fibrates via activation of PPARα (Barbier et al., 2003) .
Fibrates have also been demonstrated to increase bilirubin glucuronidation activity (Lilienblum et al., 1982) . In a study by Emi et al. (1995) , clofibrate induced UGT1A1 mRNA and had lesser effects on UGT1A5 mRNA. This is in agreement with the present study, in which, all three PPARα activators induced UGT1A1 in liver, whereas only the PPARα activator DEHP induced UGT1A5. Our data suggest that in rat, UGT1A1 is a PPARα target gene and that exposure to PPs can potentially increase its mRNA expression in liver.
This article has not been copyedited and formatted. The final version may differ from this version. and inducibility of these UGTs by the AhR ligand 3-methylcholantherene (Emi et al., 1995) . UGT1A6 and UGT1A7 are also inducible by the Nrf2 activator, oltipraz (Grove et al., 1997; Kessler and Ritter, 1997) . A recent study demonstrated that the Nrf2 activator oltipraz is capable of activating AhR, triggering binding of the AhR/ARNT heterodimer to XREs, thereby mediating transcription of UGT1A6 through the AhR pathway (Auyeung et al., 2003) . More recently, UGT1A6 and 1A7 induction by oltipraz was abrogated in Nrf2-null mice, suggesting a major role for Nrf2 in induction of these genes by oltipraz (Iida et al., 2004 duodenum. This is in agreement with a previous study that examined harmol and acetaminophen glucuronidation following TCDD treatment (Goon and Klaassen, 1992) , but in disagreement with Kobayashi et al., (1998) who saw induction of UGT1A7 in duodenum following administration of β-napthoflavone, as shown by 1-napthol glucuronidation. A potential reason for the discrepancy between this study and (Kobayashi et al., 1998) is the route of administration of β-bapthoflavone, which was given orally in their study.
Similar to AhR ligands, both Nrf2 activators induced hepatic expression of UGT1A6 and 1A7. However, both Nrf2 activators also induced hepatic expression of UGT2B1 and 2B3. In contrast to AhR ligands, Nrf2 activators also induced expression of UGTs in duodenum. UGT2B12 mRNA expression was induced by Nrf2 activators, ethoxyquin and oltipraz, whereas UGT1A2, 1A3, and 2B3 were induced, but only by oltipraz.
In conclusion, the regulation of inducible expression of UGTs is complex and needs more in depth study as to the specific mechanisms of regulation. This study was to indicate potential mechanisms of regulation of UGT isoforms in rat liver and duodenum. Each individual UGT has its own inducible profile. Some UGTs were not induced by any treatment whereas others were induced by many treatments. Several UGT1A isoforms were readily induced in liver but not Total RNA was isolated from liver and mRNA levels were evaluated using branched DNA signal amplification analysis. Data are reported as relative light units (RLU) /10 µg Total RNA. Statistical significance was accepted at p < 0.05 and is denoted by an asterisk (*). 
